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Summary
BACKGROUND: Worldwide, diabetes has become the
most common cause of end-stage renal disease (ESRD),
yet Swiss data are largely lacking.
METHODS: This observational study examined ESRD pa-
tients with diabetes mellitus (ESRD-DM) at end of 2009
and 2014. The prevalence and characteristics of ESRD-
DM patients were collected in all dialysis facilities in the
Canton of Vaud of Switzerland in 2009 and in 2014, and
the 5-year mortality rate was assessed.
RESULTS: A total of 107 and 140 ESRD-DM patients un-
derwent dialysis at end of 2009 and 2014, respectively.
Within the 5-year period a total of 167 incidental ESRD-
DM patients required dialysis, corresponding to an esti-
mated incidental rate of 0.84/1000 person-years in the di-
abetic population. In 2009, all patients with ESRD-DM un-
derwent haemodialysis, decreasing to 96.2% in 2014, with
3.8% on peritoneal dialysis. Age, sex, body mass index,
type of diabetes, duration of diabetes, cause of ESRD,
dialysis duration, dialysis frequency, vascular access, and
glycosylated haemoglobin levels did not differ between
2009 and 2014. In 2014, macrovascular comorbidity was
reported more often than in 2009, but not amputations.
Haemoglobin level decreased significantly from 117.9 g/l
to 112.3 g/l. Calcium-containing phosphate binder and an-
giotensin-converting enzyme inhibitor use significantly de-
creased, whereas iron therapy significantly increased with
time. The 5-year mortality rate was 61.7%. Five-year sur-
vivors were significantly younger and had a higher body
mass index.
CONCLUSIONS: The growing prevalence of ESRD-DM
emphasises that prevention of chronic kidney disease and
its progression should be a public health priority in
Switzerland.
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Introduction
Diabetes, one of the major noncommunicable diseases in
global health, has become the most common cause of end-
stage renal disease (ESRD) in most countries. The total
cost of renal replacement therapy (RRT) to the global
health insurance system has increased owing to the aging
population and high prevalence of type 2 diabetes. The
number of patients with ESRD receiving RRT is projected
to reach 2.2 million by the year 2030 [1–3].
Overall incidence rates of ESRD, which rose for decades,
began to stabilise or even fall after 2006 in several Eu-
ropean countries (Austria, Spain, Denmark, Sweden, Nor-
way, Finland) [4], although they continued to increase in
the USA [5], the UK [6], Taiwan [7] and Japan [8]. Trends
in ESRD with diabetes (ESRD-DM) incidence also dif-
fered according to geography [9]. The incidence of ESRD-
DM has increased in the UK over the past 10 years [6],
as well as in France [10], while it stabilised at the end of
the 2000s in the USA and has decreased since 2006 in the
USA, Denmark [11], Australia and New Zealand [12].
An understanding of these basic differences in the epi-
demiology of diabetic nephropathy is of great importance
to the development and implementation of prevention and
management strategies. Several prospective and observa-
tional studies, including those from the Dialysis Outcomes
and Practice Patterns Study (DOPPS), the United States
Renal Data System (USRDS) and the European Renal As-
sociation – European Dialysis and Transplantation Associ-
ation (ERA-EDTA) Registry have offered insights into the
characteristics and prognosis of patients with ESRD, in-
cluding ESRD-DM patients. Since Switzerland is not rep-
resented in these databases, local epidemiological data are
largely lacking.
In order to evaluate the prevalence of ESRD-DM and its
possible progression over time, we carried out a multicen-
tre study in the Canton of Vaud of Switzerland with a re-
ferral population of around 750 000 inhabitants. The pri-
mary goal of this study was to assess the prevalence and
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compare the characteristics of diabetic subjects on renal re-
placement therapy (RRT) on 31 December 2009 with those
on RRT on 31 December 2014. The secondary goals were
to examine the 5-year mortality rate of diabetic subjects on
RRT on 31 December 2009 and to examine the total num-
ber of new cases of diabetic patients on RRT during the
5-year period.
Methods
In collaboration with the dialysis facilities of the Canton
of Vaud, all files of patients with the diagnosis of diabetes
and on RRT for more than 3 months on 31 December 2009
and on 31 December 2014 were carefully examined on-
site. We collected the sociodemographic, clinical, labora-
tory and healthcare characteristics of patients actively on
RRT on 31 December 2009 and 2014 and their 5-y survival
rate. The body mass index (BMI) calculation was based on
the dry weights listed at the end of 2009 and 2014. Labo-
ratory values were considered valid for listing if obtained
within 3 months prior to data collection. Systolic and di-
astolic blood pressure values before dialysis were aver-
aged from three listed blood pressure measurements from
the three last consecutive dialysis sessions of the year. The
same was done for systolic and diastolic blood pressure
values measured at the end of dialysis. The diagnostic cri-
teria for diabetes were consistent with the American Dia-
betes Association (ADA) 2008 clinical practice guideline
[13]. The diagnosis of macrovascular complications, coro-
nary artery disease, peripheral artery disease, stroke and
other complications were based on the listing of diagnoses
in the patient file. The analysis of medications was based
on prescriptions in patient files for the two time-points: the
end of 2009 and end of 2014. The frequency of therapies
in the intervening period was not evaluated.
The following seven dialysis centres participated to this
study: the Service of Nephrology, University Hospital of
Lausanne (CHUV); Cecil Clinic, Lausanne; Northern Vaud
Hospital, Yverdon; Broye Intercantonal Hospital, Payerne;
Nyon Hospital; EHC Hospital, Morges, the Hem Unit;
Riviera Providence Hospital, Vevey. All study participants
provided written informed consent. This study was ap-
proved by the Human Research Ethics Committee, Lau-
sanne University Hospital and University of Lausanne.
Patients with diabetes who started dialysis after 31 Decem-
ber 2009 and continued it for more than 3 months, but were
not listed on 31 December 2014 were identified retrospec-
tively in 2015 and included in the assessment of the total
number of diabetic subjects on RRT during the 5-year pe-
riod.
All statistical analyses were conducted with Stata 14.1
(Stata College Station, TX). The first analysis compared
characteristics of patients listed in 2009 and 2014. Differ-
ences in baseline characteristics were tested with Fisher’s
exact test for categorical variables and Student’s test for
normally distributed continuous variables; otherwise the
Wilcoxon rank-sum test was used. The normality assump-
tion was checked graphically using the quantile-quantile
plots and tested with the Shapiro-Francia tests. The second
analysis concerned only the cohort of 2009, the purpose
being to identify factors associated with the survival 5
years after. Complete data sets were available for 101 of
107 patients in 2009, among whom 3 were lost to follow-
up by 2014. The clinical characteristics and survival curve
were thus analysed for the 98 remaining. Overall cumu-
lative survival by time since 2009 was calculated by the
Kaplan-Meier estimator. A univariate Cox regression mod-
el was used to assess differences in clinical characteristics
of survivors and nonsurvivors. The strength of the associ-
ation was measured using the calculated HR (hazard ratio)
and associated p-value. A level of p <0.05 was considered
statistically significant. We did not adjust a multivariable
model because of the insufficient size of the sample.
Results
On 31 December 2009 and on 31 December 2014, the
number of patients with ESRD-DM and the number of
those on RRT in the Canton of Vaud were 107 and 140,
respectively, corresponding to an increase in prevalence of
diabetes in the dialysis centres of the Canton de Vaud from
38% in 2009 to 47% in 2014 (fig. 1).
When those who underwent RRT for more than 3 months
during the 5-year period, but were not listed at the dates
mentioned above were included, an additional 167 new pa-
tients with ESRD-DM required dialysis in the Canton of
Vaud. This corresponds to a total number of 274 patients
with ESRD-DM during the 5-year interval and a 31% in-
crease in the number of ESRD-DM patients on RRT in
2014 compared with 2009. There was no clear trend in the
annual incidence during the 5-year period (incidental cas-
es: 2010, 37; 2011, 24; 2012, 46; 2013, 25; 2014, 35). The
estimated number of adult diabetics in the Canton de Vaud
provided by the Programme Cantonal Diabète (pcd.dia-
bete-vaud.ch) was 40 000. The average annual incidence
rate was therefore calculated as: (167/(40 000*5))*1000 =
0.835.
The clinical characteristics of ESRD-DM patients on 31
December 2009 and on 31 December 2014 are shown in ta-
bles 1 and 2. Complete data sets were available for 101 of
107 patients in 2009 and 132 of 140 patients in 2014; thus
the detailed characteristics of these patients are present-
ed. Mean age of patients was 69.5±10.5 years in 2009 and
68.9±11.7 years in 2014; over 85% had type 2 diabetes.
There was no difference in age, sex, BMI, type of diabetes,
duration of diabetes, cause of ESRD, dialysis duration or
type of vascular access between the groups. Duration of di-
abetes was available for 47 patients in 2009 and 51 patients
in 2014 and did not differ between groups. Some of the
patients developed diabetes after dialysis (8.5% in 2009;
5.9% in 2014). Only 27.3% of patients had a kidney biop-
Figure 1: Percentage of subjects on renal replacement therapy
(RRT) in the Canton of Vaud with and without diabetes on day of
listing.
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sy, and thus the cause of ESRD was most often clinically
based. Diabetes alone as a primary and unique cause of ES-
RD was reported in 15.2% of ESRD-DM patients in 2009
and in 8.5% of patients in 2014. On the other hand, 66.7%
ESRD patients had begun dialysis with diabetes and oth-
er kidney diseases in 2009 and 75.2% in 2014. The mean
dialysis duration was 3.3 years and was not significantly
different between the two groups. In 2009, no dialysed pa-
tients with diabetes were on peritoneal dialysis. In contrast,
five patients were on peritoneal dialysis in 2014.
Patients with diabetes on dialysis in 2014 had significantly
more reported macrovascular complications than those in
2009 (82.6% vs 56.4%, p <0.001), with a predominance
of coronary artery disease and peripheral artery disease.
There was no difference in amputation or diabetic foot ul-
cer rates between the two groups. Ophthalmology reports
were most often lacking; it was thus not possible to evalu-
ate accurately the prevalence of diabetic retinopathy.
There was no difference in glycated haemoglobin (HbA1c)
level (table 2) and insulin treatment between the two
groups (table 3). Haemoglobin level decreased significant-
ly from 117. ±10.9 g/l in 2009 to 112.3±11.6 g/l in 2014 (p
<0.001).
There was no difference in erythropoietin therapy between
the two groups, but the use of intravenous iron therapy
increased significantly during the study period (65.4% vs
78.8%, p = 0.02). Use of angiotensin-converting enzyme
inhibitors (ACEIs) decreased significantly (18.8% vs
7.6%, p = 0.04). On the other hand, there was no difference
in use of other antihypertensive drugs between two groups.
Use of calcium-containing phosphate binders also de-
creased (78.2% vs 46.2%, p <0.001), but there was no in-
crease in use of other phosphate binders. There was no dif-
Table 1: Basic characteristics of end-stage renal disease patients with diabetes in 2009 and 2014.
2009 (n = 101) 2014 (n = 132)
Mean SD n (%) Mean SD n (%) p-value
Age (y) 69.5 10.5 68.9 11.7 0.8
Sex 0.9
Male 69 (68.3%) 91 (68.9%)
Female 32 (31.7%) 41 (31.1%)
BMI (kg/m2) 27.0 4.4 27.9 5.2 0.3
Diabetes type 0.8
1 10 (10.3%) 11 (8.4%)
2 86 (88.7%) 118 (90.1%)
MODY 1 (1.0%) 1 (0.8%)
LADA 0 1 (0.8%)
NODAT 0 1 (0.8%)
Diabetes duration (y)
(range)
19.4 (3–42) 9.7 18.5 (0–47) 11.3 0.5
% diabetes diagnosed af-
ter start of RRT
8.5% 5.9%
Cause of ESRD 0.2
Diabetes as a unique
cause
15 (15.2%) 11 (8.5%)
Diabetes and other caus-
es
66 (66.7%) 97 (75.2%)
Not diabetic 18 (18.2%) 21 (16.3%)
Missing 4 5
Dialysis duration (y) 3.3 3.6 2.7 3.1 0.2
<1 y 18 (18.6%) 31 (23.7%)
1–2 y 20 (20.6%) 19 (14.5%)
2–3 y 11 (11.3%) 33 (25.2%)
3–4 y 16 (16.5%) 12 (9.2%)
4–5 y 7 (7.2%) 14 (10.7%)
>5 y 25 (25.9%) 22 (16.9%)
Mode of renal replace-
ment therapy
0.05
HD 101 (100%) 127 (96.2%)
PD 0 5 (3.8%)
Number of dialysis ses-
sions of HD
0.1
3/w 97 (97%) 123 (93.2%)
2/w 2 (2%) 1 (0.8%)
Other 1 (1%) 8 (6.1%)
Type of access 0.2
Native AV fistula 57 (56.4%) 66 (50.8%)
Tunnalised catheter 19 (18.8%) 26 (20%)
Prosthetic AV graft 25 (24.8%) 33 (25.4%)
PD catheter 0 5 (3.9%)
AV = arteriovenous; BMI = body mass index; ESRD = end-stage renal diseaseHD = haemodialysis; LADA = latent autoimmune diabetes of the adult; MODY = maturity onset
diabetes of the young; NODAT = new onset diabetes after transplantation; PD = peritoneal dialysis; SD = standard deviation
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ference in vitamin D, calcimimetics and statin therapies
between two groups.
The estimated 5-year mortality rate was 61.7%, based on
the outcomes of 98 diabetic patients listed by the end of
Table 2: Clinical characteristics of end-stage renal disease patients with diabetes in 2009 and 2014.
2009 (n = 101) 2014 (n = 132)
Mean SD n (%) Mean SD n (%) p-value
SBP (mm Hg)
Before dialysis 145.9 19.6 145.1 20.4 0.8
After dialysis 136.5 19.8 139.1 20.9 0.3
Difference 9.4 (˗33–63) 17.6 5.6 (˗50–48) 17.7 0.1
DBP (mm Hg)
Before dialysis 69.8 12.9 66.4 12.8 0.08
After dialysis 68.1 12.8 64.9 12.4 0.08
Difference 1.7 (˗29–33) 10.8 1.3 (˗40–37) 9.5 0.7
HR (bpm)
Before dialysis 75.5 11 76.1 13.9 0.7
After dialysis 76.3 12.7 75.1 11.9 0.5
Difference ˗0.8 (˗30–18) 8.1 0.7 (˗31–26) 9.1 0.2
Reported comorbidities
Macrovascular 57 (56.4%) 109 (82.6%) <0.001
CAD alone 13 (12.9%) 23 (17.4%)
Stroke alone 4 (4.0%) 2 (1.5.%)
PAD alone 15 (14.9%) 29 (21.8%)
CAD and stroke 3 (3.0%) 7 (5.3%)
CAD and PAD 17 (16.8%) 38 (28.8%)
Stroke and PAD 2 (2.0%) 2 (1.5%)
CAD, stroke and PAD 3 (3.0%) 11 (8.3%)
Amputation 21 (20.8%) 20 (15.2%) 0.2
Diabetic foot ulcer 22 (21.8%) 37 (28%) 0.4
Biochemistry
HbA1c (%) 6.9 1.8 6.9 1.1 0.7
Haemoglobin (g/l) 117.9 10.9 112.3 11.6 p<0.001
CAD = coronary artery disease; DBP = diastolic blood pressure; HbA1c = glycated haemoglobin; HR = heart rate; PAD = peripheral artery disease; SBP = systolic blood pressure
Table 3: Medications used by end-stage renal disease patients with diabetes in 2009 and 2014.
2009 (n = 101) 2014 (n = 132)
n (%) n (%)
p-value
Insulin 68 (71.6%) 95 (72%) 0.8
Antihypertensive drugs 90 (89%) 112 (84.8%) 0.4
ACEI 19 (18.8%) 10 (7.6%) 0.017
ARB 37 (36.6%) 44 (33.3%) 0.6
CCB 45 (44.6%) 44 (33.3%) 0.2
BB 48 (47.5%) 60 (45.5%) 0.7
Diuretics 52 (52.5%) 75 (56.8%) 0.6
Spironolactone 2 (2%) 3 (2.3%) 0.9
Minoxidil 2 (2%) 1 (1%) 0.4
Clonidine 3 (3%) 0 (0%) 0.05
Moxonidine 4 (4%) 11 (8.3%) 0.2
Phosphate binders 83 (82.2%) 67 (50.8%) <0.001
Calcium-containing 79 (78.2%) 61 (46.2%) <0.001
Aluminium-containing 5 (4.9%) 4 (3,0%) 0.5
Sevelamer 17 (16.8%) 11 (8.3%) 0.05
25-hydroxy-vitamin D 30 (29.7%) 35 (26.5%) 0.2
1,25-hydroxy-vitamin D 39 (38.6%) 42 (32.1%) 0.3
Cinacalcet 10 (9.9%) 18 (13.6%) 0.4
Statins 58 (57.4%) 81 (61.4%) 0.9
Iron 66 (65.35%) 104 (78.8%) 0.017
ESA 85 (84.2%) 104 (78.8%) 0.2
Darbepoetin 46 (45.5%) 79 (59.9%) 0.03
Epoetin alpha 0 (0%) 0 (0%)
Epoetin beta 15 (14.9%) 1 (0.8%) <0.001
Methoxypolyethylene glycol-epoetin beta 25 (24.8%) 25 (19.7%) 0.3
ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; BB = beta blockers; CCB = calcium channel blockers; ESA = erythropoiesis stimulating
agents
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2009 and followed up for 5 years (fig. 2). Factors signif-
icantly associated with mortality rate were age, BMI and
dialysis duration (table 4). The total number of patients re-
ceiving a kidney transplant during the 5-year period was 23
out of a total of 274 on RRT during the 5-year period.
Discussion
According to data from the International Diabetes Federa-
tion [14], the prevalence of diabetes in adults aged between
20 and 79 years was 7.7% in 2015, with a total estimat-
ed number of 480 700 adults with diabetes in Switzerland.
Diabetes has already become the most prevalent noncom-
municable disease in developed countries, and its epidemic
increase has also reached developing countries. Data from
USRDS has demonstrated that the number of incident ES-
RD cases with diabetes as the primary cause has been ris-
ing rapidly since 1980 [4]. Data from Switzerland are lack-
ing. The Swiss Society of Nephrology has only recently (in
2013) created the Swiss Renal Registry and Quality As-
sessment Program (SRRQAP) in order to collect informa-
tion in the dialysis population. Other epidemiological RRT
Figure 2: Kaplan Meier 5-year survival curve for patients listed in
2009.
studies in Switzerland have demonstrated that quality of
care influences survival [15], that survival rates compared
favourably with those in other countries and did not dif-
fer in diabetic patients [16], and finally that there was an
overall increase in the elderly dialysis population with time
[17]. In a prior study reported by Golshayan et al. [18], the
prevalence of diabetes among ESRD patients was 23% in
1999 in Canton Vaud, with a total of 43 diabetic patients on
RRT. Our study is the first to focus specifically on the clin-
ical characteristics of patients with diabetes on RRT and to
describe the epidemiological changes over 5 years of ES-
RD-DM patients in Canton Vaud, Switzerland.
In our study, the prevalence of ESRD-DM was 38% in
2009, and increased to 47% in 2014. The increase between
1999 (23%) and 2009 (38%) could be due to aging of the
population (62.1±11.2 years in 1999 vs 69.5±10.5 years in
2009). However, the mean age did not differ between 2009
and 2014, suggesting that other contributors are involved,
such as the increasing prevalence of type 2 diabetes and
a growing population (1.6% annual increase). Of interest,
at the end of 2015, the SRRQAP register included 4215
dialysed patients. The median age of the dialysis popula-
tion was 70.2 years and 33.7% had diabetes as a comorbid-
ity, among whom 19.7% had diabetes as the primary cause
of ESRD. We could not find an explanation for the differ-
ence in prevalence of diabetes in ESRD patients accord-
ing to the SRRQAP registry and in our study. On the other
hand, the increased prevalence of ESRD-DM and the char-
acteristics of these patients in our study were consistent
with other studies in Europe [6, 10]. From these results, we
extrapolate around 400 incidental cases of ESRD-DM pa-
tients per year starting RRT in Switzerland, corresponding
to 49.4 per million population which is slightly higher than
the average of 32 p.m.p in most European countries [19].
Several important points were observed in our study.
Firstly, there was no use of peritoneal dialysis in the treat-
ment of ESRD-DM in 2009. The choice of dialysis modal-
ity is based on financial, cultural and socioeconomic fac-
tors, as well as experience with peritoneal dialysis and
Table 4: Clinical characteristics of 5-year survivors vs nonsurvivors (total n = 98) and comparison by univariate Cox regression analysis.
Cox univariate analysisNonsurvivors*(n = 60) Survivors*(n = 38)
HR (95% CI) p-value
Age (y) 72.1±10.1 64.9± 0.1 1.04 (1.01–1.07) 0.002
Sex (M/F) 68/32% 69/31% 1.10 (0.6–1.9) 0.7
Diabetes type (1/2/other) 3.5/95/1.5% 21.6/78.4/0% 2.02 (0.7–5.5) 0.13
Duration of dialysis (y) 3.3±3.9 3.0±3.0 0.86 (0.76–0.96) 0.003
Duration of diabetes (y) 18±8.7 21±2.3 1.0 (0.94–1.02) 0.3
BMI (kg/m2) 26.1±4.1 28.3±0.7 0.93 (0.87–0.99) 0.02
SBP (mm Hg) 144.6±2.5 146.6±3.0 1.00 (0.98–1.02) 0.9
DBP (mm Hg) 68.5±13 70.8±11.9 1.00 (0.98–1.02) 1.0
ΔSBP (before and after dialysis) 8.7±15 9.0±20.4 1.00 (0.99–1.02) 0.8
ΔDBP (before and after dialysis) 2.2±9.3 0.05±12 1.01 (0.99–1.04) 0.4
Pulse (bpm) 75.8±11.6 74.5±10.2 1.00 (0.98–1.03) 0.8
Δ pulse ˗0.45±8.8 ˗1.32±7.3 1.00 (0.97–1.04) 0.8
HbA1c 6.8±1.9 7.0±1.7 0.94 (0.78–1.13) 0.5
Haemoglobin (g/l) 116.2±10.6 120.3±11.1 0.98 (0.95–1.0) 0.08
Drug therapy
Statins 69% 56% 0.76 (0.46–1.29) 0.3
Calcium-containing phosphate
binders
77% 79% 1.10 (0.56–2.18) 0.8
EPO 79% 87% 1.37 (0.65–2.89) 0.4
BMI = body mass index; DBP = diastolic blood pressure; EPO = erythropoietin; HbA1c = glycated haemoglobin; SBP = systolic blood pressure * Mean ± standard deviation or
frequency (%)
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availability of haemodialysis [20]. However, after a recent
Swiss national effort to promote home dialysis and to re-
duce the costs of RRT, more diabetic patients used peri-
toneal dialysis, as observed in our study, in 2014.
Secondly, patients with diabetes in 2014 had more
macrovascular complications than those dialysed in 2009,
a difference that was mainly dictated by the increase in pe-
ripheral arterial disease. As the amputation rate had not in-
creased, we believe that this observation was due to the
increased awareness and care of the diabetic foot imple-
mented in the Canton de Vaud in recent years, with a pro-
gramme supported by the cantonal authority (Programme
Cantonal Diabète). In addition, there may be a reporting
bias resulting from an increase in disease listing by hos-
pitalists under economic pressure after diagnosis-related
groups (DRGs) were introduced into the payment system
for inpatient care in 2012, with the intention to improve
cost efficiency [21].
Thirdly, haemoglobin level decreased significantly during
the study period from 117.9 g/l to 112.3 g/l, although it re-
mained at the target level recommended by the guidelines
[15]. Collectively, TREAT [22], CREATE [23], CHOIR
[24] studies have shown that higher haemoglobin targets
are associated with an increased risk of stroke and throm-
boembolic events in patients with chronic renal disease.
Another meta-analysis has demonstrated increased mortal-
ity associated with higher haemoglobin targets [25]. There-
fore, international guidelines recommend haemoglobin
levels of between 100 and 110 g/l [26], which probably ex-
plains the decrease in haemoglobin levels observed in this
study.
Fourthly, there was a decreased use of calcium-containing
phosphate binders. Of note, calcium administration signifi-
cantly increases calcium balance [27, 28], which could ag-
gravate vascular calcification and lead to increased cardio-
vascular mortality.
The 5-year survival rate for patients on RRT in 2009 was
around 40%. Similar numbers for diabetic and nondiabetic
patients have already been reported by Breidhardt et al. in
a Swiss cohort study of haemodialysis patients [16]. Inter-
estingly, in contrast to their cohort, in our study BMI was
significantly higher in survivors, which is in accordance
with the well-described reverse paradox in dialysis patients
[29]. It also suggests that body protein-energy wasting in
diabetic patients with RRT may be specifically linked to a
worse outcome, as found in patients presenting with “burnt
out diabetes” [30]. The finding that survival was associat-
ed with dialysis duration is possibly explained by selection
bias due to the cross-sectional design of the study: patients
were in general included not at the initiation of haemodial-
ysis, but years later. It is well known that mortality rates
are high the first year after dialysis initiation; these patients
were underrepresented in this study [31].
Of all the 274 ESRD-DM patients treated during the 5
years, only 8.4% received a kidney transplant, which is low
and underscores the need for improving access to kidney
transplantation in diabetic patients.
The main limitation of the study is the retrospective analy-
sis of patients with diabetes starting RRT but not listed
in 2009 and 2014. We believe that some patients may
have been missed, although the error is presumably weak.
The diagnosis of diabetes may have been missed in pa-
tients presenting with burnt out diabetes and no longer on
antidiabetic medication. Accurate prevalence of diabetic
retinopathy is lacking in our study owing to incomplete
reporting of ophthalmological examinations. Reported co-
morbidities were based only on the listing of diagnosis,
which may have been incomplete.
In conclusion, epidemiological changes in diabetes mel-
litus, especially type 2 diabetes, over the past 20 years
have greatly influenced the epidemiology of diabetes-relat-
ed kidney diseases. The marked increase in the prevalence
of ESRD-DM in the Canton of Vaud, may represent a so-
cioeconomic pressure on Swiss public health provisions.
Acknowledgments
We thank the Programme Cantonal Diabète Vaud for supporting this
study.
Financial disclosure
Programme Cantonal Diabète Vaud.
References
1 Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al.
Chronic kidney disease as a global public health problem: approaches
and initiatives - a position statement from Kidney Disease Improving
Global Outcomes. Kidney Int. 2007;(3):247–59. http://dx.doi.org/
10.1038/sj.ki.5002343. PubMed.
2 Meguid El Nahas A, Bello AK. Chronic kidney disease: the global chal-
lenge. Lancet. 2005;(9456):331–40. http://dx.doi.org/10.1016/
S0140-6736(05)17789-7. PubMed.
3 Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes
care guidelines and current care patterns in the United States CKD popu-
lation: National Health and Nutrition Examination Survey 1999-2004.
Am J Nephrol. 2009;(1):44–54. http://dx.doi.org/10.1159/000201014.
PubMed.
4 United States Renal Data System. 2015 USRDS annual data report: Epi-
demiology of kidney disease in the United States. National Institutes of
Health, National Institute of Diabetes and Digestive and Kidney Dis-
eases, Bethesda, MD. 2015.
5 Foley RN, Collins AJ. End-stage renal disease in the United States: an
update from the United States Renal Data System. J Am Soc Nephrol.
2007;(10):2644–8. http://dx.doi.org/10.1681/ASN.2007020220.
PubMed.
6 Hill CJ, Fogarty DG. Changing trends in end-stage renal disease due to
diabetes in the United kingdom. J Ren Care. 2012;(Suppl 1):12–22.
http://dx.doi.org/10.1111/j.1755-6686.2012.00273.x. PubMed.
7 Huang YY, Lin KD, Jiang YD, Chang CH, Chung CH, Chuang LM, et
al. Diabetes-related kidney, eye, and foot disease in Taiwan: an analysis
of the nationwide data for 2000-2009. J Formos Med Assoc.
2012;(11):637–44. http://dx.doi.org/10.1016/j.jfma.2012.09.006.
PubMed.
8 Hanafusa N, Nakai S, Iseki K, Tsubakihara Y. Japanese society for dial-
ysis therapy renal data registry-a window through which we can view
the details of Japanese dialysis population. Kidney Int Suppl (2011).
2015;(1):15–22. http://dx.doi.org/10.1038/kisup.2015.5. PubMed.
9 Annual Report of the Dialysis Outcomes and Practice Patterns Study:
Hemodialysis Data 1997-2011. Ann Arbor, MI: Arbor Research Collab-
orative for Health; 2012.
10 Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C; Au Nom du
Registre REIN. The essential of 2012 results from the French Renal Epi-
demiology and Information Network (REIN) ESRD registry. Nephrol
Ther. 2015;(2):78–87. http://dx.doi.org/10.1016/j.nephro.2014.08.002.
PubMed.
11 Sørensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized inci-
dence of diabetic patients referred for renal replacement therapy in Den-
mark. Kidney Int. 2006;(1):187–91. http://dx.doi.org/10.1038/
sj.ki.5001516. PubMed.
12 Grace BS, Clayton P, McDonald SP. Increases in renal replacement
therapy in Australia and New Zealand: understanding trends in diabetic
nephropathy. Nephrology (Carlton). 2012;(1):76–84. http://dx.doi.org/
10.1111/j.1440-1797.2011.01512.x. PubMed.
13 American Diabetes Association. Standards of medical care in dia-
betes--2008. Diabetes Care. 2008;(Suppl 1):S12–54. http://dx.doi.org/
10.2337/dc08-S012. PubMed.
14 International Diabetes Federation. Diabetes in Switzerland - 2015 [Inter-
net]. 2015 Dec [cited 2016 Mar 15] Available from: http://www.idf.org/
membership/eur/Switzerland.
Original article Swiss Med Wkly. 2017;147:w14458
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 6 of 7
15 Saudan P, Kossovsky M, Halabi G, Martin PY, Perneger TV; Western
Switzerland Dialysis Study Group. Quality of care and survival of
haemodialysed patients in western Switzerland. Nephrol Dial Trans-
plant. 2008;(6):1975–81. Published online December 25, 2007.
http://dx.doi.org/10.1093/ndt/gfm915. PubMed.
16 Breidthardt T, Moser-Bucher CN, Praehauser C, Garzoni D, Bächler K,
Steiger J, et al. Morbidity and mortality on chronic haemodialysis: a
10-year Swiss single centre analysis. Swiss Med Wkly. 2011;:w13150.
Published online February 18, 2011. doi: http://dx.doi.org/10.4414/
smw.2011.13150. PubMed.
17 Lehmann PR, Ambühl M, Corleto D, Klaghofer R, Ambühl PM. Epi-
demiologic trends in chronic renal replacement therapy over forty years:
a Swiss dialysis experience. BMC Nephrol. 2012;(1):52. Published on-
line July 04, 2012. http://dx.doi.org/10.1186/1471-2369-13-52.
PubMed.
18 Golshayan D, Paccaud F, Wauters JP. [Epidemiology of end-stage renal
failure: comparison between 2 Swiss cantons]. Nephrologie.
2002;(4):179–84. Article in French. PubMed.
19 Registry ERA-EDTA. ERA-EDTA Registry Annual Report 2014. Acad-
emic Medical Center, Department of Medical Informatics, Amsterdam,
the Netherlands, 2016.
20 Wauters JP, Uehlinger D. Non-medical factors influencing peritoneal
dialysis utilization: the Swiss experience. Nephrol Dial Transplant.
2004;(6):1363–7. http://dx.doi.org/10.1093/ndt/gfh090. PubMed.
21 Biller-Andorno N, Zeltner T. Individual Responsibility and Community
Solidarity--The Swiss Health Care System. N Engl J Med.
2015;(23):2193–7. http://dx.doi.org/10.1056/NEJMp1508256. PubMed.
22 Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D,
Eckardt KU, et al.; TREAT Investigators. A trial of darbepoetin alfa in
type 2 diabetes and chronic kidney disease. N Engl J Med.
2009;(21):2019–32. http://dx.doi.org/10.1056/NEJMoa0907845.
PubMed.
23 Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris
D, et al.; CREATE Investigators. Normalization of hemoglobin level in
patients with chronic kidney disease and anemia. N Engl J Med.
2006;(20):2071–84. http://dx.doi.org/10.1056/NEJMoa062276.
PubMed.
24 Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al.;
CHOIR Investigators. Correction of anemia with epoetin alfa in chronic
kidney disease. N Engl J Med. 2006;(20):2085–98. http://dx.doi.org/
10.1056/NEJMoa065485. PubMed.
25 Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg
AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients
with chronic kidney disease. Ann Intern Med. 2010;(1):23–33.
http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00252.
PubMed.
26 Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work
Group. KDIGO clinical practice guideline for anemia in chronic kidney
disease. Kidney Int. 2012; (suppl).
27 Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM,
et al. Oral calcium carbonate affects calcium but not phosphorus balance
in stage 3-4 chronic kidney disease. Kidney Int. 2013;(5):959–66.
http://dx.doi.org/10.1038/ki.2012.403. PubMed.
28 Spiegel DM, Brady K. Calcium balance in normal individuals and in pa-
tients with chronic kidney disease on low- and high-calcium diets. Kid-
ney Int. 2012;(11):1116–22. http://dx.doi.org/10.1038/ki.2011.490.
PubMed.
29 Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and
fat in chronic kidney disease: questions about survival. Nephrol Dial
Transplant. 2008;(8):2461–6. Published online April 09, 2008.
http://dx.doi.org/10.1093/ndt/gfn053. PubMed.
30 Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-
out diabetes in ESRD. Semin Dial. 2010;(2):148–56. Published online
April 09, 2010. http://dx.doi.org/10.1111/j.1525-139X.2010.00701.x.
PubMed.
31 Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P,
Anker SD, et al.; ARO Steering Committee. High cardiovascular event
rates occur within the first weeks of starting hemodialysis. Kidney Int.
2015;(5):1117–25. http://dx.doi.org/10.1038/ki.2015.117. PubMed.
Original article Swiss Med Wkly. 2017;147:w14458
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 7 of 7
